Myriad Genetics (NASDAQ: MYGN) reported Q4 EPS of $0.32, $0.06 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $187.92 million.

GUIDANCE:

Myriad Genetics sees Q1 2017 EPS of $0.25-$0.27, versus the consensus of $0.43. Myriad Genetics sees Q1 2017 revenue of $167-170 million, versus the consensus of $192.0 million.

Myriad Genetics sees FY2017 EPS of $1.00-$1.10, versus the consensus of $1.65. Myriad Genetics sees FY2017 revenue of $740-760 million, versus the consensus of $755.5 million.

For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.

Earnings Guidance Hot Guidance Trading Halts

Jefferies Remains Sidelined on Myriad Genetics (MYGN) Following 4Q August 11, 2016 8:37 AM Barclays Downgrades Myriad Genetics (MYGN) to EqualweightAugust 10, 2016 7:40 AM Mizuho Securities Cuts Price Target on Myriad Genetics (MYGN) to $22 Following 4Q and Guidance August 10, 2016 7:19 AM Wells Fargo Downgrades Myriad Genetics (MYGN) to Market PerformAugust 10, 2016 7:03 AM Piper Jaffray Downgrades Myriad Genetics (MYGN) to NeutralAugust 10, 2016 6:38 AM Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial ResultsAugust 9, 2016 4:06 PM Myriad Genetics (MYGN) halted with news pendingAugust 9, 2016 4:00 PM